rituximab [MabThera]

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Lymphocytic Leukemia, ChronicRheumatoid Arthritis

Phase 1

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

CompletedNCT01292603

Hoffmann-La RocheLymphocytic Leukemia, Chronic

Start: 2011-04-18End: 2017-11-17Updated: 2018-12-19

Phase 3

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

CompletedNCT02079532

Hoffmann-La RocheRheumatoid Arthritis

Start: 2006-11-30End: 2010-11-30Updated: 2016-07-29

Related Papers

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.

2016-03-0134 citations

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.

2015-07-2930 citations